Fasudil hydrochloride combined with immunotherapy for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 5 Jul 2024: Trial started, NCT07250542
  2. 26 Nov 2025: Trial registered, NCT07250542

The trials

NCT07250542: A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer

State
Under way
Phase
Phase 2
People
30 planned
Started
5 Jul 2024
Primary completion
30 Dec 2025
Arms
The group treated with farsulide hydrochloride combined with immunotherapy
Results
None posted
  1. 5 Jul 2024: Trial started
  2. 26 Nov 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.